GSK has been putting its money where its mouth is, and Witty says the last six drugs it launched in the ... in the last year or two as its flagship diabetes franchise, centred around insulin ...

Existing drugs lose their effectiveness over time, and side effects limit compliance. Beyond the GLP1 analogues and DPP4 inhibitors, the diabetes pipeline includes compounds targeting sodium ...

The European Medicines Agency (EMA) has approved two drugs ... and GlaxoSmithKline's Tivicay. Xigduo (dapagliflozin and metformin hydrochloride) is a combination treatment for type 2 diabetes ...

Originally developed for diabetes, GLP-1 agonists ... Like the other players on this list, GSK does have some weight loss drugs in its pipeline. But the focus among many investors is the company ...

Now that the U.S. government has negotiated prices for some Medicare program drugs effective in 2026, Wall Street analysts ...

Rosiglitazone, the diabetes drug taken by up to 100,000 people in the UK has been ... which was released to the market 10 years ago for people with type 2 diabetes. GlaxoSmithKline, which produces ...

The controversy over Sirtris drugs reached a tipping point in January with a publication by Pfizer researchers led by Kay Ahn showing that resveratrol activates SIRT1 only when linked to a ...

The British pharma said its shot didn’t meet the efficacy goals of a Phase 2 study. Elsewhere, Zealand reported more obesity ...

The Food and Drug Administration expanded the approval of GSK's respiratory syncytial virus ... underlying chronic conditions ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, ...